Most pharma companies have patient programmes. Very few have a Supported Treatment strategy — a governed, evidence-backed model designed into the product from the outset and built to outlast brand transitions, budget cycles, and patent cliffs. This is where that work begins.
→ Define the strategic architecture for a Supported Treatment model aligned to your product lifecycle and therapeutic area
→ Map the patient journey from first prescription through long-term persistence, identifying the moments where intervention creates the most clinical and commercial value
→ Translate patient journey insights into a prioritised support design: what to build, when, for whom, and through which channels
→ Establish the governance model — ownership, funding structure, KPIs, and cross-functional accountability — that makes the programme durable rather than fragile
→ Design the evidence strategy: how the programme will generate adherence, persistence, and real-world outcome data that supports label ambitions and payer discussions
→ Define the Product + Service model and assess patentability and regulatory positioning, including FDA PDURS and EU MDR pathways
→ Develop the internal business case for Supported Treatment investment, framed for Medical, Commercial, and C-suite audiences
→ Advise on pre-launch integration: how to build the programme into Phase 2/3 trial design so evidence generation begins before approval
→ Benchmark your current programme maturity against industry and cross-therapeutic standards, and define the roadmap to the next level
→ Support affiliate rollout planning: how global strategy translates into local execution without local reinvention